Imagine beating breast cancer — only for it to come back a year later in the other breast.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, exposes why so many breast cancer patients relapse — and how precision oncology could have prevented it. Standard protocols and limited RNA blood tests often miss key drivers, leaving patients on the wrong medications 90% of the time.
Dr. Prato reveals how Envita’s OncoMeta precision ecosystem uses DNA/RNA sequencing, immune spatial biology, and adaptive monitoring to detect the smallest signs of recurrence before it happens. Instead of another round of toxic chemo and surgery, patients receive custom-designed, microdosed therapies like Genetically Targeted Fractionated Chemotherapy (GTFC), cryoablation, and immune retraining to destroy cancer while preserving strength.
🎯 What You’ll Learn in This Episode:
• Why standard testing misses hidden tumor drivers
• The critical role of immune typing and spatial biology
• How OncoMeta connects testing, drug design, and delivery in one system
• Why cryoablation can replace surgery and preserve immune antigens
• How circulating tumor cell monitoring prevents relapse early
• Why precision care restores health while protecting the immune system
📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak to a care coordinator: 866-830-4576
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
You can read the full peer-reviewed study at:
https://www.scirp.org/journal/paperinformation?paperid=132493
